Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Comment by GiveMeMoneyon Dec 10, 2020 5:05pm
134 Views
Post# 32082142

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CRDL will rise like a Phoenix

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CRDL will rise like a Phoenix Six months later...their product isn't 'superior', it's the same - there's only one type of pharma produced 100% THC free cbd and everyone in the USA has it now and BioVectra in Canada can do the same with larger q's so this co has no moat at all.

We've been listening to pie-in-the-sky now for...years now and, as said, the market is simply getting tired of it as reflected in the SP and even if these trials turn out, what exactly is the market for it, other than from what comes out of CRDL's mouth? And, if they do have a heart prod., at their pricing prowess, what plan is going to pay for it? And what generic will come riight out with it soon-after?

What's holding it above $2 is beyond anyone's guess and can only be explained as pumpers trading between each other in low volumes trying to save a sinking ship that they have too much $ tied up in that they don't want to lose.

Belongs on the TSV.

AGAIN!!! https://www.youtube.com/watch?v=AIWaJC3_-PE
<< Previous
Bullboard Posts
Next >>